Skip to main
TOI

TOI Stock Forecast & Price Target

TOI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Starling Oncology is positioned as a strong investment opportunity due to their focus on value-based care, adherence to clinical guidelines, and strong growth in their specialty pharmacy segment. Their recent refinancing has improved their liquidity and operating flexibility, allowing them to invest in growth and manage costs effectively. However, competition and potential issues with drug pricing and reimbursement must be monitored. Considering the trading multiples of peer companies, Starling Oncology's stock price is expected to follow a reasonable growth trajectory, with a price target of $8. There are also challenges facing Starling Oncology, such as recruitment and retention of healthcare professionals and potential changes in reimbursement rates, that must be managed to maintain their success in the healthcare industry.

Bears say

Starling Oncology is a community oncology services provider facing intense competition from larger players and independent oncologists. Its growth potential is limited by its geographic footprint and high leverage. With uncertainties around reimbursement pressures and potential for membership declines, the company faces significant risks to its financial performance and ability to scale.

TOI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Oncology Institute (TOI) Forecast

Analysts have given TOI a Strong Buy based on their latest research and market trends.

According to 4 analysts, TOI has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Oncology Institute (TOI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.